Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
Summary
Vivoryon reported Q1 2026 results and updated investors on its kidney disease program. The company highlighted supportive Phase 2 data for varoglutamstat and said it wants to move into a Phase 2b study in advanced diabetic kidney disease. It continues to pursue strategic partnerships and due diligence with multiple biopharma parties and investors. Vivoryon also reconfirmed that its cash should fund operations into Q4 2026, but it still needs additional capital to continue development and stay viable beyond that point.
Funding
Amount
-
Total raised
Date
-
Announcement date
Investors
Probiodrug
Lead investors
Company
-
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected